Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Slides:

Advertisements

Similar presentations

EMT correlates with PERK but not IRE1 signaling in primary human tumors. EMT correlates with PERK but not IRE1 signaling in primary human tumors. A, two.

Advertisements

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

ETV1 positively regulates KIT expression through direct binding to KIT enhancers in human GIST cells and forms a positive feedback circuit in GIST oncogenesis.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

Recombinant OPCML protein effect in vitro.

RAS/RAF pathway-activated ovarian cancer cells exhibit MEK dependence and synergistic induction of apoptosis with combined MEK/AKT inhibition. RAS/RAF.

AKT dependence of ovarian cancer cell lines.

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

NF1 downregulation activates MAPK pathway signaling.

COX-2–PGE2 signaling is required for MSC-induced increase in ALDHhigh CSC-enriched population and tumor initiation. COX-2–PGE2 signaling is required for.

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

EGFR is intrinsically active in FGFR3-activated cell lines with combination efficacy from targeting both EGFR and FGFR3. EGFR is intrinsically active in.

Imipramine and promethazine induce the apoptotic cell death of SCLC cells through activation of caspase-3. Imipramine and promethazine induce the apoptotic.

Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK inhibitors. Signaling induced by BRAF L597R and L597S is sensitive to BRAF and MEK.

Role of HER2 in mediating acquired resistance to EGFR inhibition.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

ROS induction and ATR inhibition synergize in inducing multiple myeloma (MM) cell death. ROS induction and ATR inhibition synergize in inducing multiple.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.

Inhibition of lung cancer cell proliferation and viability by CYT387.

GA blocks HIF activity and reduces HIF target expression.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

Effect of LY on phosphorylation of various MAP kinase substrates in HeLa cells in vitro. Effect of LY on phosphorylation of various MAP kinase.

DAC treatment activates expression of immunoregulatory genes.

Inhibition of stress-associated MAPK signaling attenuates SASP expression in CAFs. A, N-CAFs were treated with 100 nmol/L GEM plus DMSO or the above-listed.

Sensor siRNAs can be used in high-order combinations.

EGFR and cetuximab sensitivity of SCCUAT

Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

Curcumin suppresses the expression of antiapoptotic proteins in multiple myeloma cells. Curcumin suppresses the expression of antiapoptotic proteins in.

The AKT–mTOR pathway controls PD-L1 protein expression.

Targeting HR via CDK inhibition resensitizes recurrent cultures to temozolomide (TMZ). Targeting HR via CDK inhibition resensitizes recurrent cultures.

ERK reactivation following EGFR TKI treatment.

Radiation does not alter AKT and MTOR gene expression.

Drug interaction signatures for GIST and benign osteoma cell lines representing all combinatorial data compiled in a 9 × 9 drug matrix. Drug interaction.

Changes in signal transduction pathway induced by gefitinib.

IGF-I partially protects Rh30 cells from apoptosis despite simultaneous inhibition of PI3K-Akt and MAP kinase pathways. IGF-I partially protects Rh30 cells.

EGFR signaling regulates transcription of PDGFRβ gene.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Pdcd4 expression inhibits AP-1 transactivation.

KRASG12D- and BRAFV600E-induced survival in PDECs requires IGF1R signaling. KRASG12D- and BRAFV600E-induced survival in PDECs requires IGF1R signaling.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

AKT activation in HCC2429 is SRC- but not Notch-dependent.

Interaction of NHEJ and HR pathways in PCO cultures.

A, left: LNCaP cells were cultured in media containing complete serum, treated for 24 hours with either ethanol control (0.01%), ABT888 (2.5 mmol/L), or.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Establishment of HeLa/rtTAA/TRE-N1-IC cell line.

Signals and transcription factors involved in B-cell PD-1 induction.

Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.

MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

Regulation of signaling by wild-type and oncogenic Ras.

Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.

NVP-BGJ398 inhibits proliferation of a subset of cancer cell lines.

T3 or T4 induces MAPK activation in myeloma cells.

A, Pharmacologically inhibiting protein tyrosine kinases significantly reduces the viability of ATRT cell lines as compared with control HEK 293 cells.

Genomic and proteomic profiling of ovarian cancer cell lines.

Inhibition of BCR-mediated signaling by ARQ 531.

miR-181a knockdown inhibits VEGF and MMP1 secretion in vitro.

JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction. JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

AXL is not necessary for maintenance of intrinsic resistance.

Bioinformatic analyses suggest that PI3K/AKT signaling may be a key downstream pathway of tazarotene signaling. Bioinformatic analyses suggest that PI3K/AKT.

Presentation transcript:

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. A, immunoblot of ETV1, pKIT, and pERK levels in GIST882 and GIST-T1 cells treated with imatinib (500 nmol/L) or MEK162 (1 μmol/L) for the indicated time points. B, ETV1 localization at the target gene loci (i.e., KIT and DUSP6) by ChIP–qPCR in GIST cells treated with imatinib (1 μmol/L) or MEK162 (500 nmol/L) for 8 hours in GIST882 cells, or imatinib (80 nmol/L) or MEK162 (500 nmol/L) for 2 hours in GIST-T1 cells. C, immunoblot of ETV1 and KIT, MAP kinase, and AKT signaling pathways in GIST882 and GIST-T1 cells treated with various doses of imatinib and MEK162 as indicated for 8 hours. D, cell viability by Alamar Blue of GIST882 and GIST-T1 cells treated with various doses of imatinib and MEK162 as indicated for 7 days. n = 3, mean ± SEM. E, cell viability by Alamar Blue of GIST-T1 cell expressing different MEK constructs treated with various doses of imatinib and MEK162 as indicated for 7 days. n = 3, mean ± SEM. F, immunoblot of ETV1, KIT, and MAP kinase signaling in GIST-T1 parental cells, GIST-T1 cells expressing MEK1WT, MEK1L115P, MEK2WT, and MEK2L119P. Cells were treated for 1 hour as indicated. V, DMSO; I, imatinib (500 nmol/L); M, MEK162 (1,000 nmol/L). Leili Ran et al. Cancer Discovery 2015;5:304-315 ©2015 by American Association for Cancer Research